葛根素注射液治疗老年急性冠脉综合征的作用及安全性观察

目的探讨葛根素注射液治疗急性冠脉综合征（ACS）的益处及安全性。方法124例ACS病人随机单盲分为两组，治疗组66例，每日给予葛根素注射液0．4g静脉输注。对照组58例，每日予安慰剂静脉输注。其余均按ACS常规治疗，连用60d后改为每月两周，随访8周和1年，观察两组住院期及随访期心脑血管事件、抗炎效果及药物不良反应。结果治疗组用葛根素注射液治疗60d后改为每月用药两周达一年．治疗组住院期反复心绞痛（AP）发作、心力衰竭（HF）、心律失常发生危险明显较对照组减少（P〈0．05）。随访期复发性心绞痛、非致死性心肌梗死、旧、需做经皮腔内冠脉成形术／冠脉旁路移植术（PCI／CABG）、因缺血发作需再住院治疗和心律失常发生明显比对照组减少（P〈0．05）。同时，葛根素注射液治疗8周后，血纤溶酶原激活物抑制剂-1（PAI-1）、纤维蛋白原（FG）、D-二聚体、C-反应蛋白（CRP）较治疗前明显降低（P〈0．01），且与对照组相比有统计学意义（P〈0．05）。结论ACS早期应用葛根素注射液治疗有效、安全，可减少住院期和随访期心脑血管事件发生。

Efficacy and Safety of Gegensu in Treatment of Acute Coronary Syndrome

Objective To evaluate the efficacy and the safety of Gegensu in patients with acute coronary syndrome (ACS).Methods One hundred and twenty-four patients (pts) with ACS were divided randomly into two groups: Pts in Therapy group( n=66) were treated with Gegensu 0.4 per day for sixty days and then two weeks a month; Pts in Control group(n=58) were given placebo. The levels of plasma lipid, C-reaction protein (CRP),fibrinogen (FIB) and D-dimer were tested before and after sixty days and one year treatment. Following up for one year the cardiovascular events or the incidence of stroke and the drug adverse reaction were monitored.Results The angina pectoris, heart failure and arrhythmia were decreased after treatment with Gegensu during hospitalization(P<0.05).In the period of following up the cardiovascular events such as recurrent angina pectoris,non-fatal acute myocardial infarction, chronic heart failure,percutaneous transluminal coronary angioplasty or coronary artery bypass graft ing and re-hospitalization were significantly lower in therapy group after sixty days treatment (P<0.05).The FIB activator inhibitor-1(PAI-1),fibrinogen,D-dimmer, CRP were lower than that before treatment in therapy group(P<0.01),and it was significantly lower comparing to control group(P <0.01). Conclusion The results suggested that Gegensu is an effective and safety for pts with acute coronary syndrome.